Day: March 22, 2023

Positive monotherapy and combination therapy data from Phase 1 trial of first clinical program, TPST-1120, announced in an oral presentation at ASCO 2022 TPST-1120 randomized combination study in first-line HCC patients with partner Roche is fully enrolled, with initial data expected in the first half of 2023 New data on TPST-1120 biomarker and proprietary small molecule TREX1 inhibitor accepted for presentation at AACR 2023 TPST-1495 Phase 1 monotherapy and combination dose escalation and optimization ongoing, with initial data release planned by mid 2023BRISBANE, Calif., March 22, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the year...

– SENTI-202 on track to submit an Investigational New Drug (IND) application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS – – Preclinical data from multiple Gene Circuit enhanced CAR NK programs to be presented at American Association for Cancer Research (AACR) Annual Meeting in April 2023 – – Cash, cash equivalents, and short-term investments of $98.6 million as of December 31, 2022; continue to expect cash runway through at least 1Q 2024 – SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter...

Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program Cash runway extended into late 2024 CTIM-76 preclinical data to be presented at AACR Annual Meeting 2023 PHILADELPHIA, March 22, 2023 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced financial results for the year ended December 31, 2022. Additionally, the Company announced a portfolio prioritization and capital allocation strategy that is expected to extend its cash runway into late 2024. The resulting changes include discontinuing the development of onapristone extended release (ONA-XR) and focusing on the development of CTIM-76, its Claudin 6 (CLDN6) bispecific antibody clinical candidate. “Given the challenging...

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022        Combination with Pherecydes announced, intending to create a global leader in extended phage therapies targeting antimicrobial resistant pathogenic bacteriaDeep restructuring implemented; team size reduced by approximately 75% since start of 2022 Cash and cash equivalents of €38.8 million ($41.5 million) at the end of December 2022Cambridge, MA (U.S.) and Lyon (France), March 22, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update for the fourth quarter and full year of 2022. “After the disappointing results of our Phase 3 trial in pancreatic cancer,...

Annual Financial HighlightsAnnual revenues of $17.8 million for 2022 improved by 10.4% from the prior year. Annual operating income of $2.4 million for 2022 was the highest since 2014. Annual net cash flows provided by operating activities were $2.5 million in 2022. Annual pre-tax income of $2.6 million, net income of $3.5 million and Pre-Corporate EBITDA of $3.9 million for 2022. $12.0 million cash and cash equivalents at December 31, 2022 was the highest balance at the end of any quarterly or annual period in Company history Annual gross billings of $70.0 million for 2022 improved 17.9% from the prior year. (in thousands) Q4 22 Q4 21 YOYChange Year Ended 2022 Year Ended 2021 YOYChangeTotal Revenues $ 4,091   $ 4,294 (4.7%) $ 17,780   $ 16,102 10.4%Operating (Loss) Income   (166 )   149 (211.4%)   2,419     2,158 12.1%(Loss)...

CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463) mitochondrial disease program. The Company previously reported clinical data in adult patients with MELAS* that indicate that zagociguat may have potential as a first-ever therapy for patients with this rare, genetic mitochondrial disease. In Q4 2022, Cyclerion met with the United States Food and Drug Administration (FDA) and incorporated feedback from regulatory and mitochondrial disease clinical experts to refine the design of a Phase 2b study to evaluate zagociguat in patients with MELAS. More recently, Cyclerion filed a request with the FDA for Orphan Drug Designation and manufactured drug product to support the Phase 2b study. Given the significant...